Literature DB >> 8938982

Identification of single and dual infections with distinct subtypes of human immunodeficiency virus type 1 by using restriction fragment length polymorphism analysis.

L M Janini1, D Pieniazek, J M Peralta, M Schechter, A Tanuri, A C Vicente, N dela Torre, N J Pieniazek, C C Luo, M L Kalish, G Schochetman, M A Rayfield.   

Abstract

The simultaneous presence of multiple HIV-1 subtypes has become common in communities with the growth of the pandemic. As a consequence, the potentiality for an increased frequency of HIV-1 mixed infections caused by viruses of distinct subtypes could be expected. Thus, there is a need to estimate the prevalence and geographic distribution of infections caused by viruses of a singular subtype as well as coinfections caused by two or more HIV-1 strains of distinct subtypes. To address this need, we have developed a genetic method based on restriction fragment length polymorphism (RFLP) to screen for these two types of infections within infected populations. In this assay, restriction enzymes may be used to predict the phylogroup of HIV-1 infected samples. A 297 bp pol fragment spanning the entire viral protease gene and a 311 bp fragment of the p24 gag region are used for this analysis. The viral regions are amplified by nested PCR using DNA templates from uncultured peripheral blood mononuclear cells (PBMC) or virus culture. Classification of HIV-1 strains to well defined subtypes B, D, F, and A/C is done by sequential endonuclease restriction analysis of a PCR amplified-protease gene followed by analysis of the p24 gag region. The electrophoretic migration patterns visualized by ethidium bromide staining or by radiolabeled probes are then determined on a 10% polyacrylamide gel. In infections caused by viruses of a singular subtype, a single restriction pattern is detected, whereas in multiple infections caused by two or more viral strains of different subtypes, the combination of different digestion patterns are observed in infected individuals. Using this methodology we have screened for genetic variations in HIV-1 proviral DNA from thirty-three Brazilian samples. Our RFLP procedure classified thirty-two samples as single infections caused by viruses of subtypes B (31) and F (1), and one sample as dual infection caused by distinct viral strains. Subsequent sequence and phylogenetic analysis of the viral protease gene in lymphocytes of all these patients confirmed our RFLP findings in single infections, and demonstrated the existence of two distinct HIV-1 strains of subtypes F and D in a patient which lymphocytes showed the simultaneous presence of two different digestion patterns. As up to now, single infections caused by subtype D variants were not identified in Brazil, our data provide the first evidence of subtype D HIV-1 in this country. Because sequencing of HIV proviral DNA is not particularly practical for large-scale molecular epidemiological studies, the protease/gag-based RFLP screening method will be useful to predict the phylogroup of HIV-1, and to identify multiple infections caused by HIV-1 strains of distinct subtypes. We believe that this information is crucial for both evaluation of the HIV-1/AIDS pandemic and intervention strategies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8938982     DOI: 10.1007/bf00576981

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  36 in total

1.  Spatial discontinuities in human immunodeficiency virus type 1 quasispecies derived from epidermal Langerhans cells of a patient with AIDS and evidence for double infection.

Authors:  M Sala; G Zambruno; J P Vartanian; A Marconi; U Bertazzoni; S Wain-Hobson
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

2.  HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions.

Authors:  M Goodenow; T Huet; W Saurin; S Kwok; J Sninsky; S Wain-Hobson
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

3.  Fast and sensitive multiple sequence alignments on a microcomputer.

Authors:  D G Higgins; P M Sharp
Journal:  Comput Appl Biosci       Date:  1989-04

4.  Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. The Transfusion Safety Study Group.

Authors:  R S Diaz; E C Sabino; A Mayer; J W Mosley; M P Busch
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

5.  Biological and molecular characterization of subtype D, G, and A/D recombinant HIV-1 transmissions in Sweden.

Authors:  T Leitner; D Escanilla; S Marquina; J Wahlberg; C Broström; H B Hansson; M Uhlén; J Albert
Journal:  Virology       Date:  1995-05-10       Impact factor: 3.616

6.  Recombination in HIV-1.

Authors:  D L Robertson; P M Sharp; F E McCutchan; B H Hahn
Journal:  Nature       Date:  1995-03-09       Impact factor: 49.962

7.  HIV-1 patients may harbor viruses of different phylogenetic subtypes: implications for the evolution of the HIV/AIDS pandemic.

Authors:  D Pieniazek; L M Janini; A Ramos; A Tanuri; M Schechter; J M Peralta; A C Vicente; N K Pieniazek; G Schochetman; M A Rayfield
Journal:  Emerg Infect Dis       Date:  1995 Jul-Sep       Impact factor: 6.883

8.  Virological and polymerase chain reaction studies of HIV-1/HIV-2 dual infection in Côte d'Ivoire.

Authors:  M Peeters; G M Gershy-Damet; K Fransen; K Koffi; M Coulibaly; E Delaporte; P Piot; G van der Groen
Journal:  Lancet       Date:  1992-08-08       Impact factor: 79.321

9.  Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology.

Authors:  F Gao; L Yue; D L Robertson; S C Hill; H Hui; R J Biggar; A E Neequaye; T M Whelan; D D Ho; G M Shaw
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

10.  Evidence for coinfection by multiple strains of human immunodeficiency virus type 1 subtype B in an acute seroconvertor.

Authors:  T Zhu; N Wang; A Carr; S Wolinsky; D D Ho
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

View more
  19 in total

1.  Genetic variability of HIV-1 protease from Nigeria and correlation with protease inhibitors drug resistance.

Authors:  A C Vicente; S M Agwale; K Otsuki; O M Njouku; D Jelpe; J A Idoko; E Caride; R M Brindeiro; A Tanuri
Journal:  Virus Genes       Date:  2001-03       Impact factor: 2.332

2.  Development and evaluation of a DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01_AE and CRF02_AG.

Authors:  Jean-Christophe Plantier; Laurence Vergne; Florence Damond; Souleymane MBoup; Eitel MPoudi-NGole; Laurence Buzelay; Isabelle Farfara; Denys Brand; Martine Peeters; Françoise Brun-Vézinet; Eric Delaporte; Francis Barin
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

3.  Longitudinal population analysis of dual infection with recombination in two strains of HIV type 1 subtype B in an individual from a Phase 3 HIV vaccine efficacy trial.

Authors:  David V Jobes; Melissa Daoust; Vivian T Nguyen; Allan Padua; Faruk Sinangil; Marcos Pérez-Losada; Keith A Crandall; Theodore Oliphant; David Posada; Andrew Rambaut; Jonathan Fuchs; Phillip W Berman
Journal:  AIDS Res Hum Retroviruses       Date:  2006-10       Impact factor: 2.205

4.  Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil.

Authors:  A Tanuri; A C Vicente; K Otsuki; C A Ramos; O C Ferreira; M Schechter; L M Janini; D Pieniazek; M A Rayfield
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

5.  Human immunodeficiency virus type 1 group m protease in cameroon: genetic diversity and protease inhibitor mutational features.

Authors:  Peter N Fonjungo; Eitel N Mpoudi; Judith N Torimiro; George A Alemnji; Laura T Eno; Esther J Lyonga; John N Nkengasong; Renu B Lal; Mark Rayfield; Marcia L Kalish; Thomas M Folks; Danuta Pieniazek
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

6.  Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from untreated Brazilian individuals.

Authors:  R Brindeiro; B Vanderborght; E Caride; L Correa; R M Oravec; O Berro; L Stuyver; A Tanuri
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

7.  Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells.

Authors:  M Janini; M Rogers; D R Birx; F E McCutchan
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.

Authors:  K Hertogs; M P de Béthune; V Miller; T Ivens; P Schel; A Van Cauwenberge; C Van Den Eynde; V Van Gerwen; H Azijn; M Van Houtte; F Peeters; S Staszewski; M Conant; S Bloor; S Kemp; B Larder; R Pauwels
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

9.  Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure.

Authors:  Rose Tsui; Belinda L Herring; Jason D Barbour; Robert M Grant; Peter Bacchetti; Alex Kral; Brian R Edlin; Eric L Delwart
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users.

Authors:  Artur Ramos; Dale J Hu; Lily Nguyen; Kim-Oanh Phan; Suphak Vanichseni; Nattawan Promadej; Kachit Choopanya; Margaret Callahan; Nancy L Young; Janet McNicholl; Timothy D Mastro; Thomas M Folks; Shambavi Subbarao
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.